RxDoctor Payments DataLook up a doctor →

Ramneet Bhathal, MD

Family Medicine · Milwaukee, WINPI 1508129545

Payments from drug & device makers

$12,291in general payments, 2019–2025

Across 667 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Johnson & Johnson$624
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$12,15699%
  • Education$1351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,291 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$170,914
Medicare patients
350
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide99$103,314
OzempicSemaglutide90$90,341
EliquisApixaban88$89,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$60,500
JanuviaSitagliptin Phosphate55$56,673
JardianceEmpagliflozin50$53,351
TrulicityDulaglutide39$44,615
RybelsusSemaglutide18$30,666
FarxigaDapagliflozin Propanediol38$30,043
XareltoRivaroxaban20$26,017
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$26,000
TradjentaLinagliptin16$16,664
KerendiaFinerenone12$15,853
EntrestoSacubitril/Valsartan15$14,871
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,372$147,929138 claims
Novo NordiskOzempic, Rybelsus$1,708$121,007108 claims
PfizerEliquis$388$89,12288 claims
Boehringer IngelheimJardiance, Tradjenta$72$70,01566 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,286$67,926100 claims
MerckJanuvia$86$56,67355 claims
AstraZenecaFarxiga, Symbicort$1,446$35,01354 claims
Johnson & JohnsonXarelto$624$26,01720 claims
BayerKerendia$309$15,85312 claims
NovartisEntresto$96$14,87115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →